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See article by Deng et al., pages 661e670 of this issue.Hypertension is a major risk factor for heart disease, renal
failure, stroke, and vascular dementia and is the single most
important cause of mortality worldwide.1 High blood pressure
is easily detected and many effective and inexpensive antihy-
pertensive drugs are available. It is a reversible condition and
when appropriately treated, cardiovascular events are signiﬁ-
cantly reduced. However, hypertension remains a major
challenge globally, with 30%-35% of adults having hyper-
tension of whom less than 30% are treated and of those only a
small proportion (10%-20%) are adequately controlled.2
Numerous factors contribute to these disappointing statistics
including the fact that exact mechanisms that cause hyper-
tension remain elusive. Blood pressure is regulated by complex
interacting physiological systems (cardiac, vascular, renal,
endocrine, neural, and immune), which are inﬂuenced by
many environmental factors.3 In addition, multiple genes
within each system, epigenetics, and epistasis (geneeenvi-
ronment interactions) contribute to blood pressure control.4
Hypertension and blood pressure are polygenic traits and
genome-wide association studies have deﬁned hundreds of
localizing quantitative trait loci (QTLs) and single-nucleotide
polymorphisms associated with blood pressure and hyper-
tension.4 Validating each genomic marker and identifying
QTL/single-nucleotide polymorphism-associated mechanistic
and functional pathways in hypertension is a massive chal-
lenge, especially as the list of genomic variants associated with
blood pressure and hypertension continues to grow.
In the current issue of the Canadian Journal of Cardiology,
Deng et al.5 focus on unravelling potential mechanisms of the
blood pressure effects of Chrm3, which encodes the muscarinic
cholinergic receptor 3 (M3R). The basis for this relates to
ﬁndings from their previous study in which they identiﬁed aReceived for publication January 27, 2019. Accepted February 6, 2019.
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salt-sensitive hypertension.6 Using congenic knock-ins, gene-
speciﬁc knockouts and ex vivo and in vivo functional studies in
the Dahl salt-sensitive rat model of polygenic hypertension,
Deng et al. showed a lone missense mutation (T1776C) in the
last intracellular domain of Chrm3, which was related to an
increase in blood pressure.5,6 Moreover, this mutation was
associated with increased M3R signalling and adrenal produc-
tion of epinephrine.5 Although these ﬁndings do not prove that
the Chrm3 mutation causes hypertension they highlight novel
prohypertensive mechanisms and pathways involving cholin-
ergic signalling and adrenal epinephrogenesis through M3R.
The cholinergic system plays an important role in regu-
lating vascular tone, by stimulating production of vasoactive
factors including nitric oxide (NO), a potent endothelium-
derived vasodilator. Cholinergic transmission involves release
of the neurotransmitter acetylcholine (ACh) followed by
activation of postsynaptic receptors of which 2 types of ACh
receptors have been identiﬁed: muscarinic and nicotinic.7
Mammals possess 5 distinct subtypes of muscarinic
receptors, M1R-M5R, which are G-protein coupled receptors
that mediate distinct responses via second messengers in
different tissues and organs. In the cardiovascular system,
vessels possess multiple muscarinic receptor subtypes,
including M1R, M2R, M3R, and M5R, whereas the heart
expresses predominantly M2Rs.7-9 Cardiac muscarinic stim-
ulation causes slowing of heart rate through direct G protein-
dependent regulation of ion channel activity and modulation
of cyclic adenosine monophosphate (cAMP)-mediated re-
sponses.8 Ach-induced stimulation of muscarinic receptors in
arteries causes contraction and relaxation depending on the
vascular bed and the integrity of the endothelium.7 The pri-
mary muscarinic response in intact vessels is vasodilation
caused by endothelial M3Rs (as well as M2Rs and M5Rs),
which increase endothelial nitric oxide synthase (eNOS)-
induced production of NO.7,10 M3Rs seem to be particularly
important because pharmacological stimulation of M3Rs with
Compound 1213, an M3R-selective ligand, was shown to
induce vasodilation and reduce blood pressure in experimental
models of pulmonary hypertension.11 In the absence ofdian Cardiovascular Society. This is an open access article under the CC BY
Figure 1. Potential mechanisms whereby a missense mutation in
Chrm3 promotes increased cholinergic signalling and stimulation of
adrenal gland production of EP, which signals through vascular adre-
noceptors. In vascular smooth muscle cells, Chrm3 receptor mutation
causes increased vascular contraction and tone and reduced vasodi-
lation leading to increased blood pressure in salt-sensitive models.
Muscarinic cholinergic receptor 3 (M3R) is expressed in multiple tis-
sues and organs represented as “target organs” in the illustration.
Thickness of arrow lines indicates predominant pathway. ACh, acetyl-
choline; N, nicotinic receptor; NE, norepinephrine; EP, epinephrine.
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injury, which is common in cardiovascular disease, ACh
causes vasoconstriction by stimulating vascular smooth muscle
cell M1R and M3R, processes associated with increased
vascular tone and blood pressure elevation.12-14
Beyond the direct vascular effects of ACh-stimulatedM3Rs,
the cholinergic system regulates blood pressure through
adrenal-derived hormones and vasoactive factors, which are also
important in hypertension.15 As highlighted in this issue of the
Canadian Journal of Cardiology, M3R-sensitive mechanisms
stimulate adrenal production of epinephrine, which in turn
inﬂuences vascular function in salt-sensitive hypertension
(Fig. 1).5 Epinephrine induces effects through multiple a and b
adrenergic receptors (adrenoceptors) in the cardiovascular sys-
tem.15,16 In the heart, epinephrine acts predominantly via
activation of b1 receptors causing positive chronotropic,
inotropic, and dromotropic effects. In vascular smooth muscle
cells epinephrine responses involve a- and b-adrenoreceptors,
causing vasoconstriction and vasodilation, respectively, with the
net functional response determined by the expression proﬁles of
adrenergic receptor subtypes. Vascular effects are largely regu-
lated by a1 adrenergic receptors, whichmediate smoothmuscle
contraction by mechanisms involving phospholipase C and
ionositol trisphosphate-dependent increases in intracellular
Ca2þ, which lead to increased vasoreactivity and vascular tone,
critically important in the pathophysiology of hypertension.17
Activation of smooth muscle b2 receptors causes relaxation,
especially important in bronchi and veins.15,16 Although
epinephrine and norepinephrine directly inﬂuence vascular
function, Deng et al. suggest that catecholamine-dependent
hypertension through M3R is in large part through the
adrenal-epinephrine-vascular axis and might be dissociated
from direct M3R-induced vascular effects.5
The concept of pharmacologically targeting muscarinic re-
ceptors to modulate norepinephrine release and vascularfunction was suggested more than 50 years ago when effects of
nicotinic drugs were tested on peripheral adrenergic nerves and
cardiac and vascular function.18 The novel pathway of
cholinergic-adrenergic cross-talk described in this issue5 of the
Canadian Journal of Cardiology highlights M3R as a putative
therapeutic target in hypertension, especially in the context of
Chrm3 mutations, increased M3R signalling, and adrenal epi-
nephrogenesis. Corroborating the ﬁndings of Deng et al.,5 early
studies showed that muscarinic antagonists inhibit norepi-
nephrine release evoked by ACh in rabbit, guinea pig, and cat
hearts and in canine saphenous vein.19-21 Additionally, nicotinic
cholinergic receptors on perivascular adrenergic nerves in cere-
bral vessels inhibit ACh-stimulated norepinephrine release.21
Blood pressure regulation and development of hyperten-
sion through interplay between cholinergic and adrenergic
transmission via muscarinic receptors is an interesting notion
that provides a platform for the integration of multiple
physiological systems (vascular, cardiac, endocrine, central
nervous system). However, the muscarinic-adrenergic axis is
very complex because multiple muscarinic and adrenergic
receptor subtypes are involved, receptors are expressed in a
tissue-speciﬁc manner, and vascular functional responses
depend on the integrity of the endothelium. In this issue
Canadian Journal of Cardiology, Deng et al.5 unravel some of
these complexities and suggest that cholinergic M3R signal-
ling through adrenergic mechanisms involving adrenal-derived
epinephrine is a novel pathway underlying hypertension.
Although this is a plausible paradigm, there are some limita-
tions that warrant consideration. First, the experiments were
conducted in a salt-sensitive model (Dahl salt-sensitive rats)
and it is unclear whether a similar M3R-dependent mecha-
nism might be functionally important in salt-independent
hypertension. Second, the study used genetic manipulation
of Chrm3 in rats. Whether CHRM3 mutations in humans also
exhibit cholinergic-adrenergic-dependent blood pressure as-
sociations is unclear. Third, there was enormous variability in
adrenal production of epinephrine when Chrm3 was down-
regulated/knocked out. Finally, the lone missense T1776C
mutation of Chrm3 was not shown to directly increase blood
pressure in Dahl-sensitive rats. Despite these shortcomings,
targeting M3R to reduce catecholamine levels and to down-
regulate the adrenergic system might be an interesting strategy
to treat hypertension. In support of this beneﬁcial metabolic
effects targeting M3R in transgenic mice have been
shown,22,23 and the M3R ligand Compound 1213 reduced
systemic and pulmonary arterial blood pressure in models of
pulmonary hypertension.11 However, it should be stressed
that muscarinic receptors play a critical role in regulating
endothelial NO release and accordingly there is a risk of
compromising vascular relaxation when muscarinic receptors
are blocked. Hence, although modulation of M3R might
indeed be an attractive therapeutic target in hypertension,
balancing the vasodilator and vasoconstrictor effects will
require careful consideration and further investigation.Funding Sources
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